ArticleIndian dermatology online journal2025
Association of Clinical Factors, IL4, and IL17 Levels with the Development of Postherpetic Neuralgia: A Prospective Study Among Patients with Herpes Zoster from India.
Article in Indian dermatology online journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence of postherpetic neuralgia (PHN) is highly variable due to the lack of a uniform definition of PHN and differing views on its severity. Most of the studies on risk factors for PHN are retrospective, and pain severity has not been uniformly graded. There is also a paucity of literature on cytokine levels as markers for the development of PHN. A few studies done so far have shown conflicting results. The objective of this study was to assess the association of clinical factors, interleukin 4 (IL4), and IL17 levels during acute zoster with the development of PHN, as well as to grade PHN using the Zoster Brief Pain Inventory (ZBPI). PATIENTS AND
methodsEighty clinically diagnosed herpes zoster cases within 1 week of the onset of the rash were recruited. The severity of prodromal pain and acute zoster pain was analyzed based on the visual analog scale and ZBPI, respectively. IL4 and IL17 estimation was done using enzyme-linked immunosorbent assay kits. Patients were followed up in the first and third months for the presence of PHN using ZBPI.
resultsPHN was present in 54 (67.5%) cases during the first month and 38 (47.5%) during the third month. Age (40-60 years; P = 0.03), trigeminal distribution (P = 0.05), lesion number between 25 and 50 (P = 0.008), presence of prodromal pain (P = 0.01), zoster-associated pain (P = 0.04), higher IL4 (P = 0.02) and IL17 (P = 0.01) levels had a significant association with PHN in the third month. Using logistic regression, PHN risk increased with increasing age. Moderate to severe PHN was present in 8 (10%) patients in the third month. No significant difference in clinical characteristics and cytokine levels was found between patients with mild and moderate to severe PHN. LIMITATIONS: Relatively small sample size.
conclusionIL4 and IL17 may be potential markers for the risk of PHN, and the role of these markers needs to be studied further.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.